Search company, investor...

Novolytics - Bacteriophage Assets

Stage

Acquired Unit | Acquired

About Novolytics - Bacteriophage Assets

Novolytics, formed in 2002, engages in the research, development, and production of phage therapy products to combat antibiotic resistance.

Headquarters Location

Sumner House St. Thomas's Road

Lancashire, England, PR7 1HP,

United Kingdom

Missing: Novolytics - Bacteriophage Assets's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novolytics - Bacteriophage Assets's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Novolytics - Bacteriophage Assets Frequently Asked Questions (FAQ)

  • Where is Novolytics - Bacteriophage Assets's headquarters?

    Novolytics - Bacteriophage Assets's headquarters is located at Sumner House, Lancashire.

  • What is Novolytics - Bacteriophage Assets's latest funding round?

    Novolytics - Bacteriophage Assets's latest funding round is Acquired Unit.

  • Who are the investors of Novolytics - Bacteriophage Assets?

    Investors of Novolytics - Bacteriophage Assets include AmpliPhi Biosciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.